<DOC>
	<DOC>NCT01511783</DOC>
	<brief_summary>The purpose of this single-center, randomized, double-blind, placebo-controlled, study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of E2609 when administered to healthy elderly subjects.</brief_summary>
	<brief_title>Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Key Healthy males and females Female subjects must be of nonchildbearing potential Aged 50 to 85 years, inclusive BMI of 18 to 32 kg/m2 at screening Thyroid function tests within normal rangeMiniMental State Examination score of 2830, inclusive Key History of neurological abnormalities, including seizures Any clinically significant abnormality of the ECG at Screening and Baseline including QTc prolongation History of ischemic heart disease, cardiac arrhythmias, cerebrovascular diseases Other medical conditions that are not stably controlled Presence of orthostatic hypotension</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>